South Korea · Delayed Price · Currency is KRW NeoImmuneTech Statistics
Total Valuation
NeoImmuneTech has a market cap or net worth of KRW 256.07 billion. The enterprise value is 220.07 billion.
| Market Cap | 256.07B |
| Enterprise Value | 220.07B |
Important Dates
The next estimated earnings date is Friday, November 6, 2026.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoImmuneTech has 98.87 million shares outstanding. The number of shares has increased by 110.94% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 98.87M |
| Shares Change (YoY) | +110.94% |
| Shares Change (QoQ) | +28.32% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | n/a |
| Float | 92.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 145.49 |
| PB Ratio | 4.54 |
| P/TBV Ratio | 7.08 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 125.04 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.83, with a Debt / Equity ratio of 0.20.
| Current Ratio | 2.83 |
| Quick Ratio | 2.68 |
| Debt / Equity | 0.20 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.48 |
| Interest Coverage | -8.43 |
Financial Efficiency
Return on equity (ROE) is -61.03% and return on invested capital (ROIC) is -25.75%.
| Return on Equity (ROE) | -61.03% |
| Return on Assets (ROA) | -21.14% |
| Return on Invested Capital (ROIC) | -25.75% |
| Return on Capital Employed (ROCE) | -36.42% |
| Weighted Average Cost of Capital (WACC) | 6.62% |
| Revenue Per Employee | 33.85M |
| Profits Per Employee | -470.15M |
| Employee Count | 52 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, NeoImmuneTech has paid 12.83 million in taxes.
| Income Tax | 12.83M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.56% in the last 52 weeks. The beta is 0.34, so NeoImmuneTech's price volatility has been lower than the market average.
| Beta (5Y) | 0.34 |
| 52-Week Price Change | -49.56% |
| 50-Day Moving Average | 1,605.06 |
| 200-Day Moving Average | 2,608.64 |
| Relative Strength Index (RSI) | 67.61 |
| Average Volume (20 Days) | 2,266,908 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NeoImmuneTech had revenue of KRW 1.76 billion and -24.45 billion in losses. Loss per share was -196.21.
| Revenue | 1.76B |
| Gross Profit | 1.51B |
| Operating Income | -21.12B |
| Pretax Income | -24.44B |
| Net Income | -24.45B |
| EBITDA | -18.29B |
| EBIT | -21.12B |
| Loss Per Share | -196.21 |
Balance Sheet
The company has 47.28 billion in cash and 11.28 billion in debt, with a net cash position of 35.99 billion or 364.06 per share.
| Cash & Cash Equivalents | 47.28B |
| Total Debt | 11.28B |
| Net Cash | 35.99B |
| Net Cash Per Share | 364.06 |
| Equity (Book Value) | 56.38B |
| Book Value Per Share | 1,490.80 |
| Working Capital | 33.25B |
Cash Flow
In the last 12 months, operating cash flow was -23.64 billion and capital expenditures -82.15 million, giving a free cash flow of -23.72 billion.
| Operating Cash Flow | -23.64B |
| Capital Expenditures | -82.15M |
| Depreciation & Amortization | 2.83B |
| Net Borrowing | -807.90M |
| Free Cash Flow | -23.72B |
| FCF Per Share | -239.93 |
Margins
| Gross Margin | 85.79% |
| Operating Margin | -1,199.82% |
| Pretax Margin | -1,388.37% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NeoImmuneTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -110.94% |
| Shareholder Yield | -110.94% |
| Earnings Yield | -9.55% |
| FCF Yield | -9.26% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 15, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | May 15, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
NeoImmuneTech has an Altman Z-Score of 3.22 and a Piotroski F-Score of 3.
| Altman Z-Score | 3.22 |
| Piotroski F-Score | 3 |